biomarin pharmaceutical inc american biotechnology company headquartered san rafael california offices facilities united states south america asia europe biomarins core business research enzyme replacement therapies erts biomarin first company provide therapeutics mucopolysaccharidosis type mps manufacturing laronidase aldurazyme commercialized genzyme corporation biomarin also first company provide therapeutics phenylketonuria years biomarin criticised drug pricing specific instances denying access drugs clinical trials biomarin founded christopher starr phd grant w denison jr investment million glyko biomedical went public seed investors amongst others mpm bioventures grosvenor fund florian biomarin acquired glyko biomarin acquired huxley pharmaceuticals inc huxley rights proprietary form amifampridine biomarin granted marketing approval european commission amifampridine phosphate treatment rare autoimmune disease myasthenic syndrome lems biomarin launched product name biomarin acquired lead therapeutics inc lead small private drug discovery early stage development company key compound orally available poly adpribose polymerase parp inhibitor studied treatment patients rare genetically defined acquisition followed purchase zystor therapeutics inc zystor privately held biotechnology company developing erts treatment lysosomal storage disorders lead product candidate fusion insulinlike growth factor alpha glucosidase development pompe rd day october biomarin also announced new program peptide therapeutic vosoritide treatment biomarin acquired zacharon pharmaceuticals private biotechnology company based san diego focused developing small molecules targeting pathways glycan biomarin acquired histone deacetylase inhibitor chemical library repligen million intention advancing work toward therapies friedreichs ataxia neurological november company agreed acquisition prosensa however range treatments duchenne muscular dystrophy failed attain fda approval development ceased may october revealed group open office dublin support growth europe middle east following illustration companys major mergers acquisitions historical predecessors comprehensive list prosensaacq zacharon pharmaceuticalsacq zystor therapeutics incacq lead therapeutics incacq huxley pharmaceuticals incacq glyko biomedicalacq biomarin six products market orphan biomarin working develop several new drugs biomarin became involved surrounding biomarin markets phosphate salt name firdapse biomarin granted exclusive licensing rights firdapse years result price prescribed national health service treatment course increased unlicensed drug firdapse company states prior licensing guaranteed quality control product way formally monitoring uncommon side effects regulatory biomarin pharmaceuticals center high profile debate regarding expanded access cancer patients experimental advice doctor andrea sloan patient advanced ovarian cancer requested company provide access bmn unapproved parp inhibitor drug candidate exhibited promising activity small phase clinical trial company declined citing safety ms sloan eventually received similar drug candidate different another controversy expanded access concerning supply drug clinical trial german child suffering brain disorder part april bbc reported patients took part trial treatment drug kuvan sapropterin hydrochloride later denied access company criticised nhs stephen hammond mp patient profiteering company commented following response biomarin disappointed nhs england recognised value treating pku patients kuvan despite decade positive patient outcomes across countries europe russia june belgian court ordered biomarin continue supplying vimizim young girl suffering morquio syndrome free charge biomarin stopped providing free vimizim beginning year negotiations belgian health authorities regarding reimbursement product repeatedly failed caused parents start legal proceedings force company keep providing medicine free charge biomarin ordered preliminary injunction keep definitive judgment would rendered medicine would available belgian market reasonable httpsenwikipediaorgwikibiomarinpharmaceutical